45 Survival advantage for carboplatin 500 mg/mg2 substituting cisplatin 120 mg/m2 in combination with vindesine and mitomycin C in patients with stage IIIB and IV squamous-cell bronchogenic carcinoma: A randomized phase III study in 221 patients
- 31 August 1997
- journal article
- abstracts
- Published by Elsevier in Lung Cancer
- Vol. 18, 14-15
- https://doi.org/10.1016/s0169-5002(97)89324-5
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: